| Date | Title | Description |
| 17.09.2026 | WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development | SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADC... |
| 16.09.2026 | WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership | SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digita... |
| 09.09.2026 | Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies | PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of an... |
| 25.08.2026 | WuXi Biologics Reports Strong Profitable Growth in H1 2026 | Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD)
IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds
EBITDA grew 3.5% Y... |
| 24.08.2026 | WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership | Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis)
Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit... |
| 19.08.2026 | Pharmaceutical Contract Manufacturing Market to Reach USD 311.95 Billion by 2030 | The global Pharmaceutical Contract Manufacturing Market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, registering a CAGR of 8.2% during the forecast period. Growth is being driven by the increasing outs... |
| 18.08.2026 | WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence | SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today an... |
| 09.07.2026 | WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy | SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Heb... |
| 08.07.2026 | WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year | Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026)
Included in the MSCI ESG Selection Indexes for the fourth consecutive year
Leader in Green CRDMO solutions for a healthier future
... |
| 30.06.2026 | WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy | WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facili... |
| 24.06.2026 | WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations | SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site... |
| 18.06.2026 | WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market | SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a G... |
| 08.06.2026 | WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards | DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life ... |
| 05.06.2026 | WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility | SINGAPORE, June 5, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at i... |
| 04.06.2026 | Middle East weekly: Invest Qatar concludes China roadshow, Core42 secures HSBC financing, Salwa REIT Fund launches, and more | Chinese companies deepen Middle East footprint Invest Qatar concludes China roadshow
Invest Qatar has concluded a China roadshow led by CEO Sheikh Ali bin Alwaleed Al-Thani and a senior delegation.
The delegation held senior-level meetings ... |
| 03.06.2026 | WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year | SHANGHAI, June 3, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the CDP Supplier Engagement Assessment (SEA)... |
| 27.05.2026 | WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities | SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian s... |
| 26.05.2026 | WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing | SUZHOU, China, May 26, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23... |
| 20.05.2026 | WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization | TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts... |
| 13.05.2026 | WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index | SHANGHAI, May 13, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in ... |
| 29.04.2026 | WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access | Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation
Enhancing governance transparency and effectiveness to create long-term value for all stakeholders
Em... |
| 24.04.2026 | WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival | CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its micr... |
| 23.04.2026 | WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics | WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Fac... |
| 15.04.2026 | WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing | Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients
Zero non-conformities demonstrates company's robust quality management system
SHANGH... |
| 30.03.2026 | WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year | SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year&quo... |
| 25.03.2026 | WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture | SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record... |
| 24.03.2026 | WuXi Biologics Reports Record 2025 Annual Results | Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)
EBITDA rose 38.1%... |
| 23.03.2026 | WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO | Revenue increased by 46.7% YoY to RMB 5,944 million
Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024
Adjusted net profit increased by 69.9% YoY to RMB 1,559 m... |
| 22.03.2026 | World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target | SHANGHAI, March 22, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impa... |
| 13.03.2026 | WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation | SINGAPORE, March 13, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two indi... |
| 02.03.2026 | WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year | SHANGHAI, March 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 (&qu... |
| 12.02.2026 | WuXi Vaccines Receives Brazil's ANVISA GMP Certification | SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturin... |
| 03.02.2026 | WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager | SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vert... |
| 29.01.2026 | WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody | SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the dev... |
| 26.01.2026 | HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline | SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologic... |
| 26.01.2026 | WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline | SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanc... |
| 15.01.2026 | JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth | Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects
209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients
Complex m... |
| 13.01.2026 | WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic | WUXI, China, Jan. 13, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility ... |
| 12.01.2026 | WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform de... |
| 19.12.2025 | WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security | SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship a... |
| 22.10.2025 | WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index | The only company from pharmaceutical industry selected for inclusion in the Index
Also included in HSI ESG Index and Hang Seng ESG 50 Index
Green CRDMO solution provider with outstanding sustainability performance
HONG KONG, Oct. 22, 2025 /... |
| 10.10.2025 | WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year | SHANGHAI, Oct. 10, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital Int... |
| 27.09.2025 | The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development | SINGAPORE, Sept. 27, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from September 24-26, 2025. The conference bro... |
| 25.09.2025 | WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability | TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability.
The platform has achieved an average mAb titer exceeding 8.0 g/L w... |
| 23.09.2025 | WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year | SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index... |
| 17.09.2025 | Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) | WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP... |
| 09.09.2025 | WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry | End-to-end Green CRDMO solutions to enable global clients for broader positive impact
Span from biologics research, development, manufacturing, and overall operations
Integration with lean management and digitalization for continuous excell... |
| 31.08.2025 | Asia markets close mixed as investors assess China’s RatingDog manufacturing data | Japanese, South Korean and Australian markets fell.
Hong Kong and Chinese stocks rise.
Asia-Pacific markets traded mixed Monday as investors assessed China’s RatingDog manufacturing data for August. The metric came in at 50.5, compared to a... |
| 28.08.2025 | WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi | Committed to net-zero across the value chain by 2050
Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- WuXi B... |
| 25.08.2025 | China Recap | Q2’s thrivers and strivers | China Recap is a weekly roundup tracking Chinese companies expanding abroad, covering market entries, funding rounds, product launches, and global partnerships.
China’s corporate globalization strategy is evolving fast. Industry giants are ... |
| 21.08.2025 | ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025 | ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025
Thu, Aug 21, 2025 08:30 CET Report this content
Hørsholm, Denmark, 21 August 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its half-y... |
| 19.08.2025 | WuXi Biologics Reports Solid 2025 Interim Results | Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2%
IFRS Gross profit margin expanded by 3.6% YoY to 42.7%
EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY
Adjusted EBITDA ... |
| 12.08.2025 | WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale | Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This ... |
| 11.08.2025 | WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules | WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules.
WuXia293Stable platform maintains stable expression ... |
| 08.08.2025 | WuXi XDC Included in MSCI China All Share Index | SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today anno... |
| 07.08.2025 | WuXi Biologics Named to A List for CDP Supplier Engagement Assessment | Earns CDP's highest rating for supply chain engagement on climate
Adds to other CDP recognition—Water Security A List and leadership score on climate change
Drives sustainability through value chain decarbonization empowerment
SHANGHAI, Aug... |
| 05.08.2025 | WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity | WUXI, China, Aug. 5, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announc... |
| 29.07.2025 | WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication | Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats.
Finished building will be one of the world's largest modular biologics... |
| 22.07.2025 | Value of Irish M&A halves in H1 but appetite for acquisitions remains | The volume of activity in the Irish mergers and acquisitions market increased slightly year-on-year in the first half of 2025, but the value of deals declined by 51 per cent from the same period last year.
The William Fry Half-Year M&A ... |
| 16.07.2025 | WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics | Best ESG rating tier of negligible-risk with a top 1% global ranking score
Industry and Regional ESG Top-Rated Company for five consecutive years
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, July 16, 2025 /PRNe... |
| 01.07.2025 | WuXi Biologics and WuXi XDC: Pioneering the Future of Biologics and Bioconjugates | In the ever-evolving landscape of biopharmaceuticals, innovation is the lifeblood that fuels progress. WuXi Biologics and WuXi XDC are at the forefront of this revolution, each carving a niche in the complex world of biologics and bioconjug... |
| 01.07.2025 | WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing | SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconj... |
| 30.06.2025 | WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL | The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL
It reduces viscosity by up to 90% while maintaining formulation stability and injectability
SHANGHAI, June 30... |
| 20.05.2025 | WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories | SHANGHAI, May 20, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announ... |
| 29.04.2025 | Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report | Contributing to United Nations Sustainable Development Goals
Enhancing transparency and effectiveness for corporate governance
Empowering employees and delivering positive impact to communities
Accelerating actions for tackling climate chan... |
| 22.04.2025 | WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year | Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals
Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future
SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("... |
| 19.04.2025 | WuXi Biologics: Pioneering the Future of Biopharmaceutical Manufacturing | In the bustling world of biopharmaceuticals, WuXi Biologics stands as a beacon of innovation. This Shanghai-based company has recently made headlines by clinching five prestigious awards at the 2025 Asia-Pacific Biopharma Excellence Awards.... |
| 18.04.2025 | WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site | - The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors
- Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20%
- As the company's largest op... |
| 14.04.2025 | WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards | SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pa... |
| 25.03.2025 | WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 | Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY
Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million
Added 151 new integrated projects, incl... |
| 24.03.2025 | WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024 | Revenue increased by 90.8% YoY to RMB 4,052 million
Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023
Net profit surged by 277.2% YoY to RMB 1,070 milli... |
| 21.03.2025 | WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year | Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6)
Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all
SHANGHAI, March 21, 20... |
| 13.03.2025 | WuXi Biologics and WuXi XDC: Pioneering the Future of Biologics and ADCs | In the fast-paced world of biotechnology, two names are making waves: WuXi Biologics and WuXi XDC. Both companies are at the forefront of innovation, pushing the boundaries of what's possible in drug development and manufacturing. Their rec... |
| 13.03.2025 | WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025 | SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in a... |
| 11.03.2025 | WuXi Biologics Included in S&P Global Sustainability Yearbook 2025 | Ranking in top 1% of S&P Global CSA Score
Inclusion in Global Yearbook for third consecutive year
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, March 11, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio&q... |
| 11.03.2025 | WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs | SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza... |
| 06.03.2025 | WuXi Biologics: Pioneering the Future of Biologics with EffiX™ and Unwavering Quality | In the fast-paced world of biotechnology, WuXi Biologics stands as a beacon of innovation. The company recently unveiled its EffiX™ Microbial Expression Platform, a game-changer in the production of recombinant proteins and plasmid DNA. Thi... |
| 04.03.2025 | WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production | - EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recom... |
| 27.02.2025 | WuXi Biologics Again Passed GMP Inspection by Japan PMDA | WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection... |
| 18.02.2025 | WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year | Ranked among the top 1% of more than 150,000 companies across 185 countries
Trusted by global partners for strong sustainability commitment
Recognized as a leader in Green CRDMO, driving innovation for a healthier future
SHANGHAI, Feb. 18, ... |
| 10.02.2025 | WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year | Ranked among the top 1% of companies assessed in the pharmaceutical industry
Recognized as a leader in Green CRDMO, driving innovation for a healthier future
Committed to creating long-term value for all stakeholders
SHANGHAI, Feb. 10, 2025... |
| 08.01.2025 | WuXi Biologics: Pioneering the Future of Biologics and Sustainability | In the bustling world of biotechnology, WuXi Biologics stands tall like a lighthouse guiding ships through foggy waters. This global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) is not just a player; it’s... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | CES 2025: A Showcase of Innovation Amidst Tensions | The Consumer Electronics Show (CES) 2025 has opened its doors in Las Vegas, showcasing a vibrant tapestry of technology and innovation. Over 1,300 Chinese companies have descended upon the event, a testament to their growing influence in th... |
| 07.01.2025 | Chinese firms display innovation and gadgets at CES 2025
China's WuXi Biologics sells Irish vaccine plant to Merck & Co
Chinese tech firms label Pentagon list as a 'clear mistake'
HDMI Forum launc... | Over 1,300 Chinese companies attended the opening of the CES show in Las Vegas on Tuesday, the world's biggest consumer electronics show held annually.
They are showing the latest technology and gadgets such as the world's biggest LED TV, a... |
| 07.01.2025 | Chinese tech firms label Pentagon list as a 'clear mistake'
Chinese firms display innovation and gadgets at CES 2025
China's WuXi Biologics sells Irish vaccine plant to Merck & Co
HDMI Forum launc... | Chinese tech giants, including SenseTime, Tencent and CATL, referred to their inclusion on a US Defense Department list of "Chinese military companies" as a "mistake" and a "false designation" on Tuesday.
They ... |
| 07.01.2025 | WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager | SHANGHAI and SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therape... |
| 02.01.2025 | WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year | Named for second consecutive year named to prestigious DJSI list
Leading green biologics solutions for a healthier future
SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Rese... |
| 14.12.2024 | The Green Revolution: Companies Leading the Charge in Sustainable Development | In a world grappling with climate change, two companies stand out for their commitment to sustainability: WuXi Biologics and Scandi Standard. Both have made significant strides in reducing their environmental impact, showcasing how business... |
| 12.12.2024 | WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection | Leading Green CRDMO Driven by Innovation for a Healthier Future
Offering End-to-end Green Biologics Solutions for the Entire Industry
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ... |
| 08.11.2024 | WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards | SHANGHAI and SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specia... |
| 28.10.2024 | WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development | SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield gluta... |
| 16.10.2024 | WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year | HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The... |
| 23.09.2024 | WuXi Biologics Included in Hang Seng ESG 50 Index | HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ES... |
| 11.09.2024 | The Rising Tide of Genomic Innovation: MGI's CycloneSEQ Technology and the Political Storm Surrounding Biotech | In the world of biotechnology, innovation is the lifeblood that fuels progress. MGI Tech Co., Ltd. has recently unveiled its latest advancements in nanopore sequencing technology, the CycloneSEQ-WT02 and CycloneSEQ-WY01. These products prom... |
| 07.09.2024 | Democrat to vote against bill restricting China's WuXi Biologics, BGI | Boards, Policy & RegulationHuman Rights
Democrat to vote against bill restricting China's WuXi Biologics, BGI
By Karen FreifeldSeptember 7, 20243:30 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Emai... |
| 21.08.2024 | WuXi XDC: A Surge in Growth and Ambition in the Bioconjugate Market | WuXi XDC Cayman Inc. is riding a wave of success. The company, a titan in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, has unveiled impressive financial results for the first half of 2024. With a revenu... |
| 21.08.2024 | WuXi Biologics Reports Solid 2024 Interim Results | Revenue increased by 1.0% YoY to RMB 8,574.2 million
Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%
Added 61 new integrated projects, including 4 from late-phase and commerci... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit increased by 175.5% to RMB 488 million,... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit increased by 175.5% to RMB 488 million,... |
